CC Stock Cash Flow Statements

The Chemours Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

The Chemours Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30

cash flows from operating activities
net income	-380,000,000	-4,000,000	-8,000,000	-27,000,000	69,000,000	52,000,000	-25,000,000	19,000,000	-376,000,000	145,000,000	-97,000,000	241,000,000	200,000,000	234,000,000	233,000,000	214,000,000	65,000,000	96,000,000	19,000,000	76,000,000	24,000,000	100,000,000	-317,000,000	76,000,000	95,000,000	94,000,000	142,000,000	275,000,000	282,000,000	297,000,000	228,000,000	207,000,000	161,000,000	151,000,000	-230,000,000	204,000,000	-18,000,000	51,000,000	-86,000,000	-29,000,000
adjustments to reconcile net income to cash from operating activities:
depreciation and amortization	92,000,000	88,000,000	78,000,000	78,000,000	74,000,000	71,000,000	74,000,000	76,000,000	78,000,000	79,000,000	74,000,000	71,000,000	72,000,000	74,000,000	75,000,000	79,000,000	80,000,000	83,000,000	80,000,000	80,000,000	81,000,000	79,000,000	79,000,000	78,000,000	78,000,000	76,000,000	71,000,000	71,000,000	72,000,000	70,000,000	69,000,000	62,000,000	71,000,000	71,000,000	72,000,000	73,000,000	73,000,000	66,000,000	66,000,000	70,000,000
gain on sales of assets and businesses	0	-1,000,000	0	0	0	-3,000,000	-4,000,000				6,000,000	0			-113,000,000	0							1,000,000	-8,000,000			0
equity in earnings of affiliates	-9,000,000	-7,000,000	30,000,000	-11,000,000	-9,000,000	-11,000,000	43,000,000	-11,000,000	-12,000,000	-9,000,000	14,000,000	-13,000,000	-14,000,000	-9,000,000	20,000,000	-12,000,000	-9,000,000	-10,000,000		-5,000,000	-7,000,000	-4,000,000	21,000,000	-9,000,000	-8,000,000	-7,000,000	22,000,000	-10,000,000	-11,000,000	17,000,000	-7,000,000	-9,000,000	-10,000,000	-7,000,000		-8,000,000	-4,000,000	-5,000,000
amortization of debt issuance costs and issue discounts	3,000,000	3,000,000	3,000,000	3,000,000	3,000,000	3,000,000	3,000,000	2,000,000	2,000,000	2,000,000	2,000,000	3,000,000	2,000,000	2,000,000	3,000,000	2,000,000	2,000,000	2,000,000	2,000,000	2,000,000	3,000,000	2,000,000	2,000,000	2,000,000	2,000,000	3,000,000	2,000,000	2,000,000
deferred tax provision										1,000,000	14,000,000			19,000,000													20,000,000	-35,000,000	3,000,000	35,000,000	30,000,000	15,000,000
asset-related charges	10,000,000	1,000,000	2,000,000				-28,000,000	112,000,000	0	11,000,000	0	0	0	5,000,000					6,000,000	5,000,000	10,000,000	1,000,000	31,000,000								0	1,000,000
stock-based compensation expense	7,000,000	5,000,000	3,000,000	5,000,000	6,000,000	1,000,000	5,000,000	6,000,000	3,000,000	4,000,000	3,000,000	7,000,000	7,000,000	10,000,000	10,000,000	4,000,000	8,000,000	12,000,000	4,000,000	3,000,000	1,000,000	8,000,000	1,000,000	4,000,000	6,000,000	8,000,000
net periodic pension cost			4,000,000	0	1,000,000	1,000,000	1,000,000	4,000,000	2,000,000	2,000,000	3,000,000	2,000,000	1,000,000	3,000,000	1,000,000	2,000,000	2,000,000	1,000,000	5,000,000	3,000,000	3,000,000	3,000,000	377,000,000	3,000,000	0	1,000,000
defined benefit plan contributions	-4,000,000	-4,000,000	-3,000,000	-2,000,000	-3,000,000	-4,000,000	-1,000,000	-2,000,000	-2,000,000	-5,000,000	-1,000,000	-2,000,000	-2,000,000	-5,000,000	-5,000,000	-4,000,000	-3,000,000	-5,000,000	-4,000,000	-3,000,000	-6,000,000	-8,000,000	-4,000,000	-2,000,000	-7,000,000	-6,000,000
other operating charges and credits	-23,000,000	37,000,000	-33,000,000	9,000,000	-7,000,000	-11,000,000	15,000,000	-9,000,000	-1,000,000	-4,000,000	3,000,000	-16,000,000	-14,000,000	6,000,000	-3,000,000	-3,000,000	-5,000,000	29,000,000	-11,000,000	-8,000,000	-6,000,000	3,000,000	0	-3,000,000	-3,000,000	4,000,000	8,000,000	-1,000,000	2,000,000	8,000,000	15,000,000	13,000,000	3,000,000	10,000,000	19,000,000				-15,000,000	-5,000,000
decrease (increase) in operating assets:
accounts and notes receivable	-63,000,000	-111,000,000	196,000,000	-59,000,000	-112,000,000	-177,000,000	202,000,000	49,000,000	-56,000,000	-205,000,000	347,000,000	83,000,000	-45,000,000	-294,000,000	118,000,000	-55,000,000	-75,000,000	-213,000,000	78,000,000	-31,000,000	139,000,000	-11,000,000	159,000,000	48,000,000	-32,000,000	16,000,000	134,000,000	88,000,000	-25,000,000	-150,000,000
inventories and other current operating assets	9,000,000	-51,000,000	-55,000,000	-76,000,000	19,000,000	-34,000,000
other non-current operating assets	16,000,000	48,000,000	-146,000,000	-4,000,000	21,000,000	31,000,000
increase in operating liabilities:
accounts payable	18,000,000	-105,000,000	86,000,000	83,000,000	-21,000,000	-157,000,000
other current operating liabilities	88,000,000	-5,000,000	-36,000,000	66,000,000	-644,000,000	-46,000,000
other non-current operating liabilities	230,000,000	9,000,000		15,000,000	-6,000,000	-5,000,000
cash from operating activities	93,000,000	-112,000,000	138,000,000	139,000,000	-620,000,000	-290,000,000	484,000,000	130,000,000	61,000,000	-119,000,000	160,000,000	301,000,000	291,000,000	2,000,000	214,000,000	311,000,000	256,000,000	39,000,000	353,000,000	299,000,000	111,000,000	44,000,000	400,000,000	288,000,000	6,000,000	-44,000,000	259,000,000	342,000,000	343,000,000	196,000,000	303,000,000	112,000,000	183,000,000	41,000,000	270,000,000	198,000,000	90,000,000	36,000,000	302,000,000	113,000,000
capex	-43,000,000	-58,000,000	-113,000,000	-28,000,000	-73,000,000	-58,000,000	-129,000,000	-63,000,000	-39,000,000	-57,000,000	-30,000,000	-71,000,000	-58,000,000	-69,000,000	-38,000,000	-66,000,000	-68,000,000	-16,000,000	-53,000,000	-47,000,000	-61,000,000	-106,000,000	-96,000,000	-128,000,000	-124,000,000	-133,000,000	-154,000,000	-116,000,000	-126,000,000	-102,000,000	0	-108,000,000	-69,000,000	-69,000,000	-103,000,000	-67,000,000	-79,000,000	-89,000,000	-127,000,000	-105,000,000
free cash flows	50,000,000	-170,000,000	25,000,000	111,000,000	-693,000,000	-348,000,000	355,000,000	67,000,000	22,000,000	-176,000,000	130,000,000	230,000,000	233,000,000	-67,000,000	176,000,000	245,000,000	188,000,000	23,000,000	300,000,000	252,000,000	50,000,000	-62,000,000	304,000,000	160,000,000	-118,000,000	-177,000,000	105,000,000	226,000,000	217,000,000	94,000,000	303,000,000	4,000,000	114,000,000	-28,000,000	167,000,000	131,000,000	11,000,000	-53,000,000	175,000,000	8,000,000
cash flows from investing activities
purchases of property, plant, and equipment	-43,000,000	-84,000,000	-109,000,000	-76,000,000	-73,000,000	-102,000,000	-135,000,000	-86,000,000	-58,000,000	-91,000,000	-67,000,000	-72,000,000	-62,000,000	-106,000,000	-83,000,000	-67,000,000	-67,000,000	-60,000,000	-53,000,000	-47,000,000	-61,000,000	-106,000,000	-96,000,000	-128,000,000	-124,000,000	-133,000,000	-154,000,000	-116,000,000	-126,000,000	-102,000,000
proceeds from sales of assets and businesses				0	0	3,000,000						0	32,000,000	1,000,000									2,000,000	6,000,000			0			39,000,000	0	1,000,000
foreign exchange contract settlements	0	-2,000,000			1,000,000	-2,000,000	0	0	-2,000,000	-6,000,000	2,000,000	2,000,000	4,000,000	-5,000,000	-3,000,000	-2,000,000	10,000,000	-17,000,000	13,000,000	10,000,000	10,000,000	-6,000,000				-1,000,000	-6,000,000	14,000,000	-11,000,000	5,000,000	-3,000,000	3,000,000	5,000,000	-3,000,000	-11,000,000			-1,000,000	-19,000,000	73,000,000
other investing activities			0	0			0				0	-4,000,000
cash from investing activities	-42,000,000	-86,000,000	-107,000,000	-75,000,000	-70,000,000	-101,000,000	-130,000,000	58,000,000	-60,000,000	-97,000,000	-65,000,000	-74,000,000	-35,000,000	-110,000,000	422,000,000	-68,000,000	-57,000,000	-77,000,000	-24,000,000	-47,000,000	-51,000,000	-112,000,000	-96,000,000	-131,000,000	-122,000,000	-134,000,000	-160,000,000	-97,000,000	-172,000,000	-58,000,000	-168,000,000	-104,000,000	-35,000,000	-63,000,000	-112,000,000	487,000,000	-68,000,000	50,000,000	-142,000,000	-32,000,000
cash flows from financing activities
proceeds from issuance of debt							0								0												0	0			1,000,000	0							1,000,000	0
debt repayments	-103,000,000	-8,000,000	-477,000,000	-8,000,000	-2,000,000	-3,000,000	-3,000,000	-271,000,000	-3,000,000	-3,000,000	-4,000,000	-57,000,000	-3,000,000	-4,000,000	-70,000,000	-757,000,000	-24,000,000	-3,000,000	-803,000,000	-6,000,000	-6,000,000	-128,000,000	-22,000,000	-9,000,000	-3,000,000	-3,000,000	-4,000,000	-3,000,000	-668,000,000	-4,000,000	-3,000,000	-4,000,000	-16,000,000	-4,000,000	-169,000,000	-117,000,000	-86,000,000	-9,000,000	-4,000,000
payments of debt issuance cost												0
payments on finance leases	-4,000,000	-3,000,000	-3,000,000	-3,000,000	-3,000,000	-3,000,000	-3,000,000	-2,000,000	-3,000,000	-3,000,000	-2,000,000	-3,000,000	-3,000,000	-3,000,000	-2,000,000	-3,000,000	-3,000,000	-2,000,000	-2,000,000	-1,000,000	-2,000,000	-1,000,000	-1,000,000
proceeds from supplier financing program	20,000,000	27,000,000		20,000,000	20,000,000	27,000,000
payments to supplier financing program	-18,000,000	-35,000,000	-22,000,000	-19,000,000	-24,000,000	-37,000,000
proceeds from exercised stock options			1,000,000	0	7,000,000	1,000,000	1,000,000	9,000,000	7,000,000	2,000,000	0	3,000,000	42,000,000	6,000,000	8,000,000	4,000,000	5,000,000	6,000,000	7,000,000	4,000,000	0	5,000,000	1,000,000	0	2,000,000	6,000,000	1,000,000	2,000,000	8,000,000	5,000,000	1,000,000	4,000,000	6,000,000	20,000,000
payments related to tax withholdings on vested stock awards	0	-1,000,000		0	-1,000,000	-2,000,000		0	0	-18,000,000		0	0	-4,000,000	0	0	0	-2,000,000	0	0	0	-2,000,000	0	0	0	-30,000,000
payments of dividends to the company's common shareholders	-13,000,000	-37,000,000	-36,000,000	-38,000,000	-37,000,000	-37,000,000	-37,000,000	-37,000,000	-38,000,000	-37,000,000	-37,000,000	-39,000,000	-38,000,000	-40,000,000	-41,000,000	-41,000,000	-41,000,000	-41,000,000	-41,000,000	-41,000,000
cash from financing activities	-27,000,000	-57,000,000	85,000,000	-27,000,000	-40,000,000	-54,000,000	-7,000,000	325,000,000	-73,000,000	-73,000,000	-190,000,000	-175,000,000	-131,000,000	-189,000,000	-201,000,000	-241,000,000	-76,000,000	-42,000,000	-197,000,000	-344,000,000	247,000,000	-155,000,000	-59,000,000	-77,000,000	41,000,000	-324,000,000	-170,000,000	-182,000,000	-370,000,000	-271,000,000	-115,000,000	-15,000,000	472,000,000	11,000,000	-166,000,000	-122,000,000	-92,000,000	-16,000,000	-8,000,000	-108,000,000
effect of exchange rate changes on cash, cash equivalents, restricted cash and restricted cash equivalents	15,000,000	6,000,000	-19,000,000	10,000,000	-4,000,000	-9,000,000	13,000,000	-11,000,000	-4,000,000	6,000,000	31,000,000	-32,000,000	-22,000,000	-9,000,000	-15,000,000
decrease in cash, cash equivalents, restricted cash and restricted cash equivalents	39,000,000	-249,000,000			-734,000,000	-454,000,000			-76,000,000	-283,000,000				-306,000,000
cash, cash equivalents, restricted cash and restricted cash equivalents at january 1,	0	763,000,000		0	0	1,807,000,000		0	0	1,304,000,000
cash, cash equivalents, restricted cash and restricted cash equivalents at june 30,
supplemental cash flows information
non-cash investing and financing activities:
purchases of property, plant, and equipment included in accounts payable	0	26,000,000	-4,000,000	48,000,000	0	44,000,000	6,000,000	23,000,000	19,000,000	34,000,000	37,000,000	1,000,000	4,000,000	37,000,000	45,000,000	1,000,000	-1,000,000	44,000,000
deferred tax benefit		-15,000,000	7,000,000	-22,000,000	-11,000,000	-1,000,000	-23,000,000	-64,000,000							-22,000,000	-16,000,000	-33,000,000	-6,000,000	-15,000,000	-35,000,000	-27,000,000	-43,000,000	-148,000,000			-7,000,000													-112,000,000	-55,000,000
cash, cash equivalents, restricted cash and restricted cash equivalents at march 31,		514,000,000				1,353,000,000				1,021,000,000				1,245,000,000
gain on extinguishment of debt							0
goodwill impairment			0
non-current operating liabilities
proceeds from sales of assets and businesses, net of cash divested
payments of debt issuance costs																											0	0
proceeds from supplier financing programs
purchases of treasury stock, at cost							0	-18,000,000	-37,000,000	-14,000,000	-144,000,000	-79,000,000	-128,000,000	-144,000,000	-93,000,000	-67,000,000							0	0	-67,000,000	-255,000,000	-124,000,000	-126,000,000
payments related to tax withheld on vested stock awards
(distributions to) cash received from non-controlling interest shareholders
other financing activities			0
increase in cash, cash equivalents, restricted cash and restricted cash equivalents			97,000,000				360,000,000				-64,000,000	20,000,000			420,000,000
cash, cash equivalents, restricted cash, and restricted cash equivalents at january 1,											0	0	0	1,551,000,000	0
cash, cash equivalents, restricted cash, and restricted cash equivalents at december 31,
cash paid during the year for:
interest, net of amounts capitalized
income taxes, net of refunds
treasury stock repurchased, not settled											-9,000,000	8,000,000	-4,000,000	6,000,000	2,000,000	0
loss on extinguishment of debt															1,000,000													0
cash received from non-controlling interest shareholder								0
cash, cash equivalents, restricted cash and restricted cash equivalents at september 30,
payments related to extinguishment of debt															0												0	0
cash received (distributions to) non-controlling interest shareholders
inventories and other operating assets								69,000,000	58,000,000	-32,000,000	-131,000,000	-173,000,000	-77,000,000	-9,000,000	-124,000,000	-18,000,000	-29,000,000	-31,000,000	15,000,000	78,000,000	75,000,000	-42,000,000	162,000,000	24,000,000	-21,000,000	-49,000,000	-111,000,000	-90,000,000	-67,000,000	-29,000,000	-117,000,000	-48,000,000	-12,000,000	-31,000,000	34,000,000	28,000,000	67,000,000	18,000,000	48,000,000	39,000,000
accounts payable and other operating liabilities								-16,000,000	437,000,000	-108,000,000	-77,000,000	90,000,000	216,000,000	-34,000,000	20,000,000	98,000,000	255,000,000	81,000,000	144,000,000	134,000,000	-179,000,000	-44,000,000	36,000,000	82,000,000	-110,000,000	-177,000,000	-33,000,000	42,000,000	48,000,000	-13,000,000	68,000,000	-192,000,000	-4,000,000	-42,000,000	360,000,000	-34,000,000	44,000,000	-38,000,000	165,000,000	-46,000,000
(gain) loss on extinguishment of debt											0
proceeds from accounts receivable securitization facility																			0	0	0	12,000,000	3,000,000
repayments on accounts receivable securitization facility
proceeds from revolving loan																			0	0			0	0
repayments on revolving loan																			0				0
deferred acquisition-related consideration
distributions to non-controlling interest shareholders															0				0	0
non-cash financing arrangements																			1,000,000				0
acquisition of business																							0				0	0
proceeds from life insurance policies															0								0
obligations incurred under build-to-suit lease arrangement																							5,000,000	5,000,000	13,000,000	17,000,000	6,000,000	15,000,000	15,000,000	11,000,000
deferred payments related to acquisition of business																							0
effect of exchange rate changes on cash and cash equivalents																	8,000,000	-17,000,000	17,000,000	17,000,000	10,000,000	-6,000,000	4,000,000	-16,000,000	8,000,000	-2,000,000	-3,000,000	-5,000,000	-18,000,000	11,000,000	1,000,000	13,000,000
increase in cash and cash equivalents																			149,000,000	-75,000,000							-74,000,000	58,000,000			21,000,000	6,000,000	631,000,000	-4,000,000	-55,000,000
cash and cash equivalents at january 1,																	0	1,105,000,000	0	0	0	943,000,000	0	0	0	1,201,000,000	0	0	0	1,556,000,000
cash and cash equivalents at june 30,
decrease in cash and cash equivalents																		-97,000,000				-229,000,000		64,000,000	-67,000,000	-504,000,000				-122,000,000
cash and cash equivalents at march 31,																		1,008,000,000				714,000,000				697,000,000				1,434,000,000
cash and cash equivalents at december 31,
changes in property, plant, and equipment included in accounts payable																			6,000,000	0	-12,000,000	37,000,000	17,000,000	93,000,000	-14,000,000	-11,000,000	25,000,000	13,000,000	0	-1,000,000
cash and cash equivalents at september 30,
payments of dividends																						-41,000,000	-40,000,000	-41,000,000	-41,000,000	-42,000,000	-42,000,000	-45,000,000
purchases of treasury stock not settled by period-end
purchases of treasury stock not settled by year-end
dividends accrued but not yet paid
purchases of treasury stock not settled by quarter-end																										6,000,000				15,000,000
tax payments accrued for withholdings on vested restricted stock units																														4,000,000
investments in affiliates
payments related to tax withholdings on vested restricted stock units																											-1,000,000	-10,000,000
gain on sale of assets and businesses																													-3,000,000	-42,000,000		0	2,000,000	-16,000,000
proceeds from sale of assets and businesses
amortization of deferred financing costs and issuance discount																														3,000,000	3,000,000	3,000,000	4,000,000	3,000,000
purchases of treasury stock at cost																														-240,000,000
tax payments related to withholdings on vested restricted stock units																														-1,000,000	-2,000,000
payment of dividends																														-31,000,000
(gain) loss on sale of assets and businesses
payment of deferred financing fees
cash provided at separation by dupont																																							0	0
net transfers to dupont
operating activities
increase in operating assets:
accounts and notes receivable - trade																																60,000,000	-67,000,000	-103,000,000	68,000,000	29,000,000	-52,000,000	-40,000,000	186,000,000	-45,000,000
investing activities
purchases of property, plant and equipment																																-108,000,000	-69,000,000	-69,000,000	-103,000,000	-67,000,000	-79,000,000	-89,000,000	-127,000,000	-105,000,000
investment in affiliates																																			1,000,000				0	0
financing activities
dividends paid																																-5,000,000	-6,000,000	-5,000,000	-6,000,000	-5,000,000	-6,000,000	-5,000,000	-5,000,000
deferred financing fees																																0				0	0	-2,000,000
cash and cash equivalents at beginning of the period																																0	0	902,000,000
cash and cash equivalents at end of the period																																6,000,000	631,000,000	898,000,000
non-cash investing activities
change in property, plant and equipment included in accounts payable																																-11,000,000	-19,000,000	14,000,000		-1,000,000	7,000,000	3,000,000		-7,000,000
deferred tax benefits																																		5,000,000	-82,000,000	7,000,000
proceeds from sales of assets and business																																		9,000,000			10,000,000	140,000,000
effect of exchange rate changes on cash																																		7,000,000			18,000,000	-1,000,000	-1,000,000
non-cash investing activites:
equity in earnings of affiliates, net of dividends received of 18, 23 and 19
asset related charges																																			15,000,000	46,000,000			15,000,000
proceeds from sales of assets																																							4,000,000	0
debt issuance costs																																							0	-2,000,000
net transfers (to) from dupont																																							0	0
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
supplemental cash flow information:
non-cash change in property, plant and equipment included in accounts payable
amortization of debt issuance costs and discount																																				4,000,000	3,000,000	8,000,000
gain on sale of assets and business																																				-170,000,000	1,000,000	-89,000,000
decrease in operating liabilities:
proceeds from sales of assets and business, net of cash transferred
cash and cash equivalents at beginning of period
cash and cash equivalents at end of period
non-cash investing activities:
other operating charges																																					-41,000,000	55,000,000
increase in cash																																					-52,000,000	69,000,000	151,000,000	-32,000,000
cash at beginning of period																																					0	366,000,000
cash at end of period																																					-52,000,000	435,000,000		-32,000,000
employee separation (credit) charges
decommissioning and other charges																																					-2,000,000	13,000,000
asset related charges - impairment 1
total																																					50,000,000	17,000,000
deferred tax expense																																						10,000,000
net transfers from dupont
employee separation charges																																						4,000,000
equity in earnings of affiliates, net of dividends received of 23, 19 and 19
cash at beginning of year
cash at end of year
selling segment
titanium technologies
fluoroproducts
chemical solutions
equity in earnings of affiliates, net of dividends received of 0 and 1																																								-7,000,000
payments of long-term capital lease obligations
supplemental disclosure of significant non-cash investing activities:
net
historical pro forma earnings per share data
earnings per share attributable to chemours
basic and diluted
weighted-average number of shares outstanding

We provide you with 20 years of cash flow statements for The Chemours stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of The Chemours stock. Explore the full financial landscape of The Chemours stock with our expertly curated income statements.

The information provided in this report about The Chemours stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.